Goat Anti-Mouse IgG2b heavy chain (HRP) (ab97250)
Key features and details
- Goat Anti-Mouse IgG2b heavy chain (HRP)
- Conjugation: HRP
- Host species: Goat
- Isotype: IgG
- Suitable for: ICC, IHC-P, ELISA, WB
Related conjugates and formulations
Overview
-
Product name
Goat Anti-Mouse IgG2b heavy chain (HRP)
See all IgG2b secondary antibodies -
Host species
Goat -
Target species
Mouse -
Specificity
By immunoelectrophoresis and ELISA this antibody reacts specifically with mouse IgG2b. Cross reactivity with other immunoglobulins is less than 2%. -
Tested applications
Suitable for: ICC, IHC-P, ELISA, WBmore details -
Conjugation
HRP
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 6.8
Constituents: 0.2% BSA, 0.05% CMIT/MIT based preservative -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
Antiserum was solid phase adsorbed to ensure subclass specificity. This antibody was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to Horse Radish Peroxidase (HRP). -
Conjugation notes
Molar enzyme/ antibody protein ratio is 4:1 -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Substrate reagent
- TMB ELISA Substrate (Highest Sensitivity) (ab171522)
- TMB ELISA Substrate (High Sensitivity) (ab171523)
- TMB ELISA Substrate (Fast Kinetic Rate) (ab171524)
- TMB ELISA Substrate (Slow Kinetic Rate) (ab171525)
- TMB ELISA Substrate (Slower Kinetic Rate) (ab171526)
- TMB ELISA Substrate (Slowest Kinetic Rate) (ab171527)
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab97250 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC |
Use at an assay dependent dilution.
|
|
IHC-P |
1/200 - 1/2000.
|
|
ELISA |
1/10000 - 1/100000. Similar dilution to primary antibody.
|
|
WB |
1/2000 - 1/25000. WB-Colorimetric 1/2000 - 1/20000; WB-Chemiluminescent 1/5000 - 1/25000
|
Notes |
---|
ICC
Use at an assay dependent dilution. |
IHC-P
1/200 - 1/2000. |
ELISA
1/10000 - 1/100000. Similar dilution to primary antibody. |
WB
1/2000 - 1/25000. WB-Colorimetric 1/2000 - 1/20000; WB-Chemiluminescent 1/5000 - 1/25000 |
Images
-
IHC image of Coilin staining in human testis formalin fixed paraffin embedded tissue section*. The section was pre-treated using pressure cooker heat mediated antigen retrieval with sodium citrate buffer (pH6) for 30mins. The section was incubated with ab87913, 3µg/ml overnight at +4°C. An HRP-conjugated secondary (ab97250, 1/500 dilution) was used for 1hr at room temperature. The section was counterstained with haematoxylin and mounted with DPX.
The inset negative control image is taken from an identical assay without primary antibody.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (34)
ab97250 has been referenced in 34 publications.
- Chen S et al. Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines. Small 19:e2205819 (2023). PubMed: 36564365
- Stoler-Barak L et al. B cell class switch recombination is regulated by DYRK1A through MSH6 phosphorylation. Nat Commun 14:1462 (2023). PubMed: 36927854
- Affonso de Oliveira JF et al. COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response. Front Microbiol 14:1117494 (2023). PubMed: 37152732
- Jia JX et al. A liposomal carbohydrate vaccine, adjuvanted with an NKT cell agonist, induces rapid and enhanced immune responses and antibody class switching. J Nanobiotechnology 21:175 (2023). PubMed: 37264420
- Chuang YM et al. A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria. NPJ Vaccines 8:88 (2023). PubMed: 37286568